Journal articleEur J Cancer2023

Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R).

DOI 10.1016/j.ejca.2022.11.035 ↗ OpenAlex, retrieved 5 November 2026

Journal: Eur J Cancer
Published: 10 December 2022
Citations: 37
Type: Article
License: cc by

These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.

Try

Trials 2

Its registry lists this paper as resultsSintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer NCT06050317 ↗
Builds on itIpilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic Cancer NCT04258150 ↗

The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.